Keyphrases
Muscle Wasting
69%
Muscle Loss
41%
Glucocorticoid-induced Osteoporosis
34%
Inflammatory Pathways
34%
Chronic Inflammatory Diseases
34%
Muscle Atrophy
34%
Acute Exacerbation of COPD (AECOPD)
34%
Hydroxysteroid Dehydrogenase
34%
Intra-articular
34%
Sustained Delivery
34%
Gellan
34%
Catabolic
24%
Murine Model
24%
Inflammation
24%
Muscle Metabolism
17%
Bone Metabolism
17%
Inflammatory Bone Loss
17%
Glucocorticoid Therapy
17%
Anti-inflammatory Properties
17%
Effective Management
17%
Steroid Metabolism
17%
Disease Management
17%
Patient Management
17%
Immunomodulatory
17%
Net Effect
17%
Anabolic Metabolism
17%
Inflammatory Diseases
17%
Pathway Interaction
17%
Disease Model
17%
Chronic Inflammation
17%
Osteoporosis
17%
Synthetic Glucocorticoids
17%
Myonuclear Accretion
13%
Acute Exacerbation
13%
Chronic Obstructive Pulmonary Disease
13%
Intratracheal
13%
Emphysema
13%
Steroid Release
13%
Synoviocytes
13%
Arthritis
13%
Inflammatory Arthritis
6%
Extra-pulmonary Complications
6%
Plasma Corticosterone
6%
Skeletal muscle Wasting
6%
Plasma Cytokines
6%
Endogenous Glucocorticoids
6%
C2C12
6%
Therapeutic Inhibitors
6%
Therapeutic Use
6%
Production Application
6%
Glucocorticoid-induced
6%
Anabolic Pathways
6%
Mass Change
6%
Human Myotubes
6%
C2C12 Myotubes
6%
Intratracheal Instillation
6%
Western Blot Analysis
6%
Computed Tomography
6%
WT Control
6%
Corticosterone Levels
6%
Exogenous Glucocorticoid
6%
Cellular Response
6%
Elastase
6%
Quantitative PCR
6%
Endogenous Production
6%
KO Mice
6%
Muscle Mass
6%
Cell Compatibility
6%
Osteoarthritis
6%
Transgenic
6%
Articular Cartilage
6%
Biocompatible Hydrogel
6%
Joint Inflammation
6%
In Situ Gelation
6%
Duration of Action
6%
Cell Suppression
6%
Extended Culture
6%
Release Assessment
6%
Pannus Formation
6%
Joint Degeneration
6%
Prednisolone
6%
Intra-articular Drug Delivery
6%
Glucocorticoid Injection
6%
Synovitis
6%
Vehicle Control
6%
Mechanics of Materials
6%
Unique Solution
6%
Preclinical Assessment
6%
Hydrogel Formulation
6%
Step Change
6%
Controlled Drug Release
6%
Sustained Release
6%
Microstructure
6%
Good Stability
6%
Fickian
6%
Shear Thinning
6%
Pharmacology, Toxicology and Pharmaceutical Science
Glucocorticoid
100%
Muscle Atrophy
44%
Chronic Obstructive Lung Disease
34%
Hydroxysteroid Dehydrogenase
34%
Gellan
34%
Arthritis
27%
Inflammatory Disease
14%
Inflammation
11%
Diseases
9%
Emphysema
8%
Controlled Drug Release
6%
Tumor Necrosis Factor
6%
Joint Degeneration
6%
Synovitis
6%
Prednisolone
6%
Osteoarthritis
6%
Pannus
6%
Sustained Release
6%
Medicine and Dentistry
Glucocorticoid
65%
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
34%
Hydroxysteroid Dehydrogenase
34%
Muscle Atrophy
34%
Gellan
34%
Arthritis
20%
Chronic Obstructive Pulmonary Disease
17%
Steroid Release
13%
Synovial Cell
13%
C2C12
8%
Myotube
8%
Emphysema
8%
Arthritis
6%
Joint Injection
6%
Prednisolone
6%
Osteoarthritis
6%
Controlled Drug Release
6%
Articular Cartilage
6%
Synovitis
6%
Pannus
6%
Tumor Necrosis Factor
6%
Joint Degeneration
6%
Sustained Drug Release
6%